Skip to main content
Start triage

Start triage first, then route to emergency care.

Start symptom intake Emergency vets near you

Need urgent help? Start triage first, then route to emergency care.

Start symptom intake Emergency vets near you

Roxee Medication Guide

Fluralaner/Moxidectin Spot-On

Medication reference facts with explicit FDA-approval, off-label, source-limited, and safety context. Roxee does not sell, prescribe, or dispense medications.

Both Reference complete FDA data linked Rx required Solution Merck Sharp & Dohme Corp. Official label facts Owner quick guide first
Start Symptom Intake Talk to a Vet / Find a Vet Near You

Veterinary professional?

Showing simplified owner view. Switch to Vet View for full technical detail.

Data freshness

Reference facts
Reference refreshed
Aug 6, 2026, 7:47 p.m.

These are the reference facts Roxee uses on browse cards and quick facts.

FDA applications
FDA application data refreshed
Aug 6, 2026, 7:47 p.m.

Sponsor, product, and application records imported from Animal Drugs @ FDA.

Safety reports
Safety data refreshed
Aug 6, 2026, 7:49 p.m.

openFDA reaction terms and case summaries are supporting evidence, not proof of causality.

Source timing details
Source timing details
  • Reference facts: Source Roxee | Refreshed Aug 6, 2026, 7:47 PM UTC
    The reference fact projection used for browse cards and quick facts.
  • Animal Drugs @ FDA: Source FDA | Refreshed Aug 6, 2026, 7:46 PM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed Aug 6, 2026, 7:47 PM UTC
    Package/product NDCs from FDA’s electronic listing directory (XLS).
  • openFDA reaction terms: Source FDA openFDA | Refreshed Aug 6, 2026, 7:52 PM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed Aug 6, 2026, 7:52 PM UTC
Illustration placeholder
Fluralaner/Moxidectin Spot-On

Fluralaner/Moxidectin Spot-On

Drug type: Generic ingredient • Branded profile • FDA branded products available

Both Solution Rx required 100% reference complete

Species: Both

Manufacturer: Merck Sharp & Dohme Corp.

Medication Snapshot

Merged from the current Roxee medication system with field-level provenance, freshness, and completeness tracking.

Fluralaner/Moxidectin Spot-On

For the prevention of heartworm disease caused by Dirofilaria immitis and for the treatment of infections with intestinal roundworm ( Toxocara cati ; 4th stage larvae, immature adults and adults) and hookworm ( Ancylostoma tubaeforme ; 4th stage larvae, immature adults and adults). Kills adult fleas and is indicated for the treatment and prevention of flea infestations ( Ctenocephalides felis ) and the treatment and control of tick infestations [ Ixodes scapularis (black-legged tick), Dermacentor variabilis (American dog tick), Haemaphysalis longicornis (Asian longhorned tick), and Amblyomma maculatum (Gulf Coast tick)] for 2 months in cats and kittens 6 months of age and older and weighing 2.6 lb or greater. Species commonly shown: Both, Cat.

Generic name
Fluralaner/Moxidectin Spot-On
Brand names
BRAVECTO® PLUS, Bravecto Plus
Manufacturer
Merck Sharp & Dohme Corp.
Species
Both, Cat
Dosage forms
Solution
Prescription
Prescription required
Completeness
100%
Validation
Complete
Brand names
BRAVECTO® PLUS Bravecto Plus
Dosage forms
Solution

Indications / Uses

For the prevention of heartworm disease caused by Dirofilaria immitis and for the treatment of infections with intestinal roundworm ( Toxocara cati ; 4th stage larvae, immature adults and adults) and hookworm ( Ancylostoma tubaeforme ; 4th stage larvae, immature adults and adults). Kills adult fleas and is indicated for the treatment and prevention of flea infestations ( Ctenocephalides felis ) and the treatment and control of tick infestations [ Ixodes scapularis (black-legged tick), Dermacentor variabilis (American dog tick), Haemaphysalis longicornis (Asian longhorned tick), and Amblyomma maculatum (Gulf Coast tick)] for 2 months in cats and kittens 6 months of age and older and weighing 2.6 lb or greater.

Side Effects

Top reported reactions (openFDA): Emesis (multiple), Ataxia, Diarrhoea, Disorientation, Hiding, Hyperactivity.

FAQ

Both, Cat

Yes. Roxee shows this as prescription-only.

Solution

Related Conditions

Fleas (Flea Infestation) Heartworm Disease Pica Tick infestation

Source Transparency

Add to My Pet's Medications

Choose a pet, confirm current or past, and optionally add reminder notes.

Sign in to save this medication to your pet profile.

Sign in to continue

Pet Owner Quick Guide

Start here first for the safest next-step summary before the deeper medication detail.

Used for:

For the prevention of heartworm disease caused by Dirofilaria immitis and for the treatment of infections with intestinal roundworm ( Toxocara cati ; 4th stage larvae, immature adults and adults) and hookworm ( Ancylosto...

Dosing note:

Exact dosing depends on your pet's species, weight, and health status. Use your veterinarian's instructions for the exact dose and schedule.

What to watch for:

  • Vomiting (1 reports)
  • wobbly/unsteady walking (1 reports)
  • very low energy (1 reports)

When to call the vet:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.
  • Facial swelling or hives.
  • Blood in vomit or stool.

What to tell or ask your vet today:

  • Is this medicine the right fit for my pet’s current symptoms?
  • Which warning signs mean I should call back right away?
  • How should I handle missed doses or refusal to take the medicine?

Next actions

Talk to a Vet / Find a Vet Near You Save to pet meds Share page Review report evidence
Research brief

Medication Research Insights

A source-aware map of what to know, what is uncertain, and what to verify with your veterinarian.

Source Backed Signals

What to know

Evidence-backed context Limited

Roxee has limited cited overview evidence for Fluralaner/Moxidectin Spot-On; use the official documents and your veterinarian's instructions for product-specific decisions.

Source: openFDA case USA-USFDACVM-2025-US-055671
Safety signal coverage Reported signals

32 tracked reaction signals; 32 reported cases; 16 serious reports; 2 species groups. These are reporting and label-derived signals for interpretation with a veterinarian.

Source: openFDA case USA-USFDACVM-2025-US-055671
Interpretation guardrail Not causation

Adverse-event reports help form a watch list, but they do not prove the medication caused the reaction and they are not a risk ranking between medications.

Evidence tension

Stronger signal Label / review

Official labels, package inserts, and reviewed summaries carry more weight than isolated reports.

Source: openFDA case USA-USFDACVM-2025-US-055671
Weaker signal Reported data

Case reports and openFDA terms are useful for pattern awareness, but they are incomplete, can include multiple exposures, and do not estimate an individual pet's probability of harm.

Reaction signal map

Most reported reactions Top terms

Vomiting (1 reports), Unsteady walking (ataxia) (1 reports), Tiredness (lethargy) (1 reports), Nausea (1 reports), Loss of appetite (1 reports)

Body systems represented Signal grouping

Digestive (5), Skin & allergy (4), Neurologic (2), Effectiveness (1)

Explore supporting adverse reports

Species and breed lens

Species represented in reports Species lens

Cat (26 reports), Dog (6 reports)

Breed metadata in reports Metadata only

Cat (unknown) (1). These are report metadata, not proof that a breed is at higher risk.

What your vet may verify

Fit for this patient Vet check

Verify whether Fluralaner/Moxidectin Spot-On fits the pet's species, current diagnosis, age, weight, organ status, pregnancy/lactation status, and concurrent medications.

Evidence limitations Evidence review

Separate label-backed warnings from adverse-event reports and owner observations before changing the plan.

What to watch next

Watch list Owner-safe

Vomiting, wobbly/unsteady walking, very low energy

Call sooner if Escalation

Repeated vomiting or diarrhea. Severe lethargy (hard to wake, very low energy). Collapse or fainting.

Bottom line: Use this Fluralaner/Moxidectin Spot-On brief as a structured watch list and source map, not as a reason to start, stop, or change treatment without your veterinarian.
Vet source depth
  1. openFDA case USA-USFDACVM-2025-US-055671 · adverse_reaction · adverse reactions
  2. FDA application profile · official_label · quick facts
  3. Medication usage source · fda_animal_drugs · quick facts
  4. FOI · document · documents
  5. FOI · document · documents
  6. FOI · document · documents
  7. SPL · document · documents
  8. Structured Product Label · document · documents

Evidence

Review status / Updated / Sources

Review status: Clinical reviewer not listed

Updated: April 22, 2026, 10:06 AM UTC

Sources:
Safety & side effects

Side effects to monitor:

  • Vomiting
  • wobbly/unsteady walking
  • very low energy

Most reported reactions:

  • Vomiting (1 reports)
  • Unsteady walking (ataxia) (1 reports)
  • Tiredness (lethargy) (1 reports)
Explore reported case details

Emergency warning signs:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.
Talk to a Vet / Find a Vet Near You Start Symptom Intake

Vet Fast Scan

Source-backed clinical checkpoints for quick review.

FDA-labeled species
Cat
Indication / use
For the prevention of heartworm disease caused by Dirofilaria immitis and for the treatment of infections with intestinal roundworm ( Toxocara cati ; 4th stage larvae, immature ad…
Form / route / dose
Form: Solution
Route: Topical
Confirm product label and patient-specific plan.
Warnings
No structured warnings linked yet.
Adverse-event caveat
openFDA adverse-event cases are reported signals. They are not verified, do not prove causation, and do not estimate a pet's individual risk.
Source docs

Quick Facts

Official label facts first, then secondary summaries. Marketing content is separated below.

Species: Both
Manufacturer: Merck Sharp & Dohme Corp.
Form: Solution
Identifiers:
NADA: 141518 NDC Package: 0061-5996-01 NDC Package: 0061-5997-01 NDC Package: 0061-5998-01 NDC Product: 0061
Source metadata:

Adverse Reactions

Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.

Reported case explorer

Filter stored openFDA reports by pet and report attributes. Counts describe reports in this data set, not risk.

Clear filters
openFDA adverse-event cases are reported signals. They are not verified, do not prove causation, and do not estimate a pet's individual risk.
Stored reports
1
Matching reports
1
Active filters
0
Reset
Drill into common report signals
Foaming at the mouth (1) Other (1)
Showing up to 50 matching reports.

USA-USFDACVM-2026-US-011251

Received 2026-02-20 · MSK · MSK

Non-serious
Species
Cat
Breed
Cat (unknown)
Size / weight
10-24 lb (5.897 Kilogram)
Age
1-3 years (3 Year)
Sex
Male Intact
Region
USA
Reactions
Foaming at the mouth
Body systems
Other
Outcomes
Recovered/Normal

Tap or hover a reaction to see what it means in plain language.

Tracked signals
32
Reported cases
32
Serious reports
16
Species represented
2
Grouped by Body System
Digestive (5) · Vomiting, Nausea, Loss of appetite Skin & allergy (4) · Itching, Hair loss NOS, Hair loss at application site Neurologic (2) · Unsteady walking (ataxia), Tiredness (lethargy) Effectiveness (1) · Lack of efficacy (ectoparasite) - flea Other (20) · Licking at application site, INEFFECTIVE, PARASITE(S) NOS, Increased heart rate
Most Reported Reactions
Reaction Body system Cases Species Serious cases
Digestive 1 Cat 1
Neurologic 1 Dog 1
Neurologic 1 Dog 1
Digestive 1 Cat 1
Digestive 1 Cat 1
Other 1 Cat 1
Other 1 Cat 1
Other 1 Cat 1

Species coverage: Cat (26) Dog (6)

View detailed reaction table
Reaction Body system Species Seriousness Frequency Reports
Digestive Cat Serious - 1
Neurologic Dog Serious - 1
Neurologic Dog Serious - 1
Digestive Cat Serious - 1
Digestive Cat Serious - 1
Other Cat Serious - 1
Effectiveness Cat Non-serious - 1
Skin & allergy Cat Non-serious - 1
Other Cat Non-serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Dog Non-serious - 1
Other Dog Non-serious - 1
Skin & allergy Cat Non-serious - 1
Skin & allergy Cat Serious - 1
Other Cat Non-serious - 1
Other Cat Non-serious - 1
Other Cat Serious - 1
Other Cat Non-serious - 1
Other Cat Serious - 1
Other Cat Non-serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Other Cat Non-serious - 1
Digestive Dog Non-serious - 1
Other Cat Non-serious - 1
Digestive Cat Serious - 1
Other Cat Non-serious - 1
Other Cat Serious - 1
Skin & allergy Cat Serious - 1
Other Cat Non-serious - 1
Other Cat Non-serious - 1
Source metadata:

Source Documents

The most useful source links appear first; full previews and metadata stay in the veterinary/professional layer.

Use original documents to confirm product-specific warnings, ingredients, and handling details with your veterinarian.

BRAVECTO® PLUS SPL · SPL Bravecto Plus SPL SPL · Structured Product Label FOI Summary sN 141-518 Approved January 13, 2026.pdf FOI · FOI

Full source previews and metadata remain in the veterinary/professional layer.

Owner handouts

0
No owner handouts linked yet.

Official label / PI

0
No official label or package insert links yet.

SPL

2

FOI

3

BRAVECTO® PLUS

SPL · SPL

Open original
FDA Structured Product Label

BRAVECTO® PLUS

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Intervet, Inc.
NADA
141-518
Status
RX
Form
Solution
Route
Topical
Species
Cat
Composition / specifications
Each milliliter contains 280 mg of fluralaner and 14 mg of moxidectin

Cats

Indication

For the prevention of heartworm disease caused by Dirofilaria immitis and for the treatment of infections with intestinal roundworm (Toxocara cati; 4th stage larvae, immature adults and adults) and hookworm (Ancylostoma tubaeforme; 4th stage larvae, immature adults and adults). Kills adult fleas and is indicated for the treatment and prevention of flea infestations (Ctenocephalides felis) and the treatment and control of tick infestations [Ixodes scapularis (black-legged tick), Dermacentor variabilis (American dog tick), Haemaphysalis longicornis (Asian longhorned tick), and Amblyomma maculatum (Gulf Coast tick)] for 2 months in cats and kittens 6 months of age and older and weighing 2.6 lb or greater.

Dosage

Administer topically as a single dose every 2 months to provide a minimum dose of 18.2 mg/lb (40 mg/kg) fluralaner and 0.9 mg/lb (2 mg/kg) moxidectin.

Bravecto Plus SPL

SPL · Structured Product Label

Open original
FDA Structured Product Label XML for Bravecto Plus. Use the source link for the full official labeling record.

FOI Summary sN 141-518 Approved January 13, 2026.pdf

FOI · FOI

Open original

FOI Summary sN 141-518 Approved August 9, 2022.pdf

FOI · FOI

Open original

FOI Summary oN 141-518 Approved November 14, 2019_.pdf

FOI · FOI

Open original
Source metadata:
Veterinary reference (advanced)

Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.

At a Glance

Quick facts and links to official labeling and safety signals.

Data freshness
  • Reference facts: Source Roxee | Refreshed Aug 6, 2026, 7:47 PM UTC
    The reference fact projection used for browse cards and quick facts.
  • Animal Drugs @ FDA: Source FDA | Refreshed Aug 6, 2026, 7:46 PM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed Aug 6, 2026, 7:47 PM UTC
    Package/product NDCs from FDA’s electronic listing directory (XLS).
  • openFDA reaction terms: Source FDA openFDA | Refreshed Aug 6, 2026, 7:52 PM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed Aug 6, 2026, 7:52 PM UTC
Official (FDA)
Identity: Generic ingredient • FDA branded products available
Official FDA brands: Bravecto Plus
Manufacturer mapping: Merck Sharp & Dohme Corp.
Case-reported brands (openFDA): MSK
Catalog species: Both • FDA-labeled species: Cat
Rx/OTC: RX
Form/route: Solution • Topical
Applications: NADA 141-518
NDC: Packages 0061-5996-01 0061-5997-01 0061-5998-01 • Products 0061
Documents: 3 (FOI: 3) • SPL: 1 • Label highlights • Official documents
Safety (openFDA)
Top reactions: Dog 0 • Cat 1 • View
Case summaries: 1 (showing 1) • View
openFDA reports are unverified and do not prove causation.
Explore
Linked using: Fda_Label (0.95), Fda_Label (0.95), Fda_Label (0.95)
Diagnosis Codes
ICD10_CM: B74.8 ICD10_CM: B88.1
Other filariases

Counseling and Monitoring Highlights

Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.

Top reaction signals
Vomiting (1) Unsteady walking (ataxia) (1) Tiredness (lethargy) (1) Nausea (1) Loss of appetite (1) Licking at application site (1) Increased heart rate (1) Hypersensitivity reaction (1)

Identifiers & Packages

Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.

Identifiers
NADA: 141518 NDC Package: 0061-5996-01 NDC Package: 0061-5997-01 NDC Package: 0061-5998-01 NDC Product: 0061
Package NDC Product NDC Form / Route Status
0061-5996-01 0061 -
0061-5997-01 0061 -
0061-5998-01 0061 -

Enriched Documents

Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.

Data Sources & Change Log

Every non-trivial field is expected to include provenance and update timestamps.

Official 120 Clinical 4 Manufacturer 0 Marketing 0
Current Field Facts
  • side_effects: Top reported reactions (openFDA): Emesis (multiple), Ataxia, Diarrhoea, Disorientation, Hiding, Hyperactivity. (Clinical, 2026-05-02)
  • side_effects: Top reported reactions (openFDA): Emesis (multiple), Ataxia, Diarrhoea, Disorientation, Hiding, Hyperactivity. (Clinical, 2026-04-22)
  • side_effects: Top reported reactions (openFDA): Emesis (multiple), Ataxia, Diarrhoea, Disorientation, Hiding, Hyperactivity. (Clinical, 2026-04-15)
  • side_effects: Top reported reactions (openFDA): Emesis (multiple), Ataxia, Diarrhoea, Disorientation, Hiding, Hyperactivity. (Clinical, 2026-04-11)
  • indications: For the prevention of heartworm disease caused by Dirofilaria immitis and for the treatment of infections with intestinal roundworm (Toxocara cati, 4th stage l… (Official, 2026-08-06)
  • indications: For the prevention of heartworm disease caused by Dirofilaria immitis and for the treatment of infections with intestinal roundworm (Toxocara cati, 4th stage l… (Official, 2026-08-05)
  • indications: For the prevention of heartworm disease caused by Dirofilaria immitis and for the treatment of infections with intestinal roundworm (Toxocara cati, 4th stage l… (Official, 2026-08-04)
  • indications: For the prevention of heartworm disease caused by Dirofilaria immitis and for the treatment of infections with intestinal roundworm (Toxocara cati, 4th stage l… (Official, 2026-08-03)
  • indications: For the prevention of heartworm disease caused by Dirofilaria immitis and for the treatment of infections with intestinal roundworm (Toxocara cati, 4th stage l… (Official, 2026-08-02)
  • indications: For the prevention of heartworm disease caused by Dirofilaria immitis and for the treatment of infections with intestinal roundworm (Toxocara cati, 4th stage l… (Official, 2026-08-01)
  • indications: For the prevention of heartworm disease caused by Dirofilaria immitis and for the treatment of infections with intestinal roundworm (Toxocara cati, 4th stage l… (Official, 2026-07-31)
  • indications: For the prevention of heartworm disease caused by Dirofilaria immitis and for the treatment of infections with intestinal roundworm (Toxocara cati, 4th stage l… (Official, 2026-07-30)
  • indications: For the prevention of heartworm disease caused by Dirofilaria immitis and for the treatment of infections with intestinal roundworm (Toxocara cati, 4th stage l… (Official, 2026-07-29)
  • indications: For the prevention of heartworm disease caused by Dirofilaria immitis and for the treatment of infections with intestinal roundworm (Toxocara cati, 4th stage l… (Official, 2026-07-28)
  • indications: For the prevention of heartworm disease caused by Dirofilaria immitis and for the treatment of infections with intestinal roundworm (Toxocara cati, 4th stage l… (Official, 2026-07-27)
  • indications: For the prevention of heartworm disease caused by Dirofilaria immitis and for the treatment of infections with intestinal roundworm (Toxocara cati, 4th stage l… (Official, 2026-07-26)
  • indications: For the prevention of heartworm disease caused by Dirofilaria immitis and for the treatment of infections with intestinal roundworm (Toxocara cati, 4th stage l… (Official, 2026-07-25)
  • indications: For the prevention of heartworm disease caused by Dirofilaria immitis and for the treatment of infections with intestinal roundworm (Toxocara cati, 4th stage l… (Official, 2026-07-25)
  • indications: For the prevention of heartworm disease caused by Dirofilaria immitis and for the treatment of infections with intestinal roundworm (Toxocara cati, 4th stage l… (Official, 2026-07-22)
  • indications: For the prevention of heartworm disease caused by Dirofilaria immitis and for the treatment of infections with intestinal roundworm (Toxocara cati, 4th stage l… (Official, 2026-07-22)
Recent Revisions
  • side_effects updated 2026-07-03 11:05 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-07-03 11:05 by etl_backfill • Backfilled from existing medication fields
  • side_effects updated 2026-05-02 10:05 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-05-02 10:05 by etl_backfill • Backfilled from existing medication fields
  • side_effects updated 2026-04-30 10:09 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-04-30 10:09 by etl_backfill • Backfilled from existing medication fields
  • side_effects updated 2026-04-22 10:07 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-04-22 10:07 by etl_backfill • Backfilled from existing medication fields
  • side_effects updated 2026-04-15 10:04 by etl_backfill • Backfilled from existing medication fields
  • side_effects updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
  • side_effects updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields

FDA Products & Applications (Animal Drugs @ FDA)

Official sponsor/proprietary-name/application-status records linked by active ingredient.

Product Sponsor Application Status Published
BRAVECTO® PLUS
RX
Fluralaner Moxidectin
Solution • Topical
Label highlights
Official documents
Intervet, Inc. NADA 141-518 Approved Feb 2, 2026

Data source: FDA Animal Drugs @ FDA (public search export).

What It's For (FDA Label Highlights)

Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.

Species: Cat
Composition / specifications
Each milliliter contains 280 mg of fluralaner and 14 mg of moxidectin
Cats
Indication

For the prevention of heartworm disease caused by Dirofilaria immitis and for the treatment of infections with intestinal roundworm (Toxocara cati; 4th stage larvae, immature adults and adults) and hookworm (Ancylostoma tubaeforme; 4th stage larvae, immature adults and adults). Kills adult fleas and is indicated for the treatment and prevention of flea infestations (Ctenocephalides felis) and the treatment and control of tick infestations [Ixodes scapularis (black-legged tick), Dermacentor variabilis (American dog tick), Haemaphysalis longicornis (Asian longhorned tick), and Amblyomma maculatum (Gulf Coast tick)] for 2 months in cats and kittens 6 months of age and older and weighing 2.6 lb or greater.

Dosage

Administer topically as a single dose every 2 months to provide a minimum dose of 18.2 mg/lb (40 mg/kg) fluralaner and 0.9 mg/lb (2 mg/kg) moxidectin.

Limitations

FDA page: Open in Animal Drugs @ FDA

Usage

For the prevention of heartworm disease caused by Dirofilaria immitis and for the treatment of infections with intestinal roundworm ( Toxocara cati ; 4th stage larvae, immature adults and adults) and hookworm ( Ancylostoma tubaeforme ; 4th stage larvae, immature adults and adults). Kills adult fleas and is indicated for the treatment and prevention of flea infestations ( Ctenocephalides felis ) and the treatment and control of tick infestations [ Ixodes scapularis (black-legged tick), Dermacentor variabilis (American dog tick), Haemaphysalis longicornis (Asian longhorned tick), and Amblyomma maculatum (Gulf Coast tick)] for 2 months in cats and kittens 6 months of age and older and weighing 2.6 lb or greater.

Source: FDA Animal Drugs @ FDA • Reference

Top Reported Reactions (openFDA)

De-duplicated reaction terms grouped by body system from FDA openFDA reports (not verified; does not prove causation).

Digestive
Vomiting (1) • Cat Nausea (1) • Cat Loss of appetite (1) • Cat Diarrhea (1) • Dog Blood in vomit (1) • Cat

Showing top 5 for Digestive.

Skin & allergy
Itching (1) • Cat Hair loss NOS (1) • Cat Hair loss at application site (1) • Cat Application site hair loss (1) • Cat

Showing top 5 for Skin & allergy.

Neurologic
Unsteady walking (1) • Dog Tiredness (1) • Dog

Showing top 5 for Neurologic.

Effectiveness
Lack of efficacy (ectoparasite) - flea (1) • Cat

Showing top 5 for Effectiveness.

Other
Licking at application site (1) • Cat INEFFECTIVE, PARASITE(S) NOS (1) • Cat Increased heart rate (1) • Cat Hypersensitivity reaction (1) • Cat Hyperactivity (1) • Dog
Show more (15)
Hiding (1) • Dog Grooming disorder (1) • Cat Foaming at the mouth (1) • Cat Fever (1) • Cat Excessive chewing, licking and/or grooming (1) • Cat Elevated temperature (1) • Cat Drug administered at inappropriate site (1) • Cat Distress (1) • Cat Disorientation (1) • Dog Dilated pupils (1) • Cat Cold feeling to the touch (1) • Cat Application site scab (1) • Cat Application site reddening (1) • Cat Application site burn (1) • Cat Application site blister (1) • Cat

Showing top 5 for Other.

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Adverse Event Case Summaries (openFDA)

These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.

Cat, Cat (unknown), Male, 3 year, 5.897 kilogram • Drug: MSK, Solution, Topical, Dose: 1 tube per animal, Frequency: 2 per month • Reactions: Foaming at the mouth • Outcome: Recovered/Normal

  • Report ID: USA-USFDACVM-2026-US-011251
  • Serious AE: No
  • Treated For AE: No
  • Sex: Male
  • Age: 3.00 Year
  • Weight: 5.897 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Topical
  • Form: Solution
  • Dose: 1 tube per animal
  • Frequency: 2 per month
Reactions Reported:
Foaming at the mouth
Outcomes: Recovered/Normal

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Overdose Information

No approved overdose-management text is linked yet. If overdose is suspected, contact a veterinarian or emergency clinic immediately.

Storage & Handling

No approved storage guidance is linked yet for this ingredient. Use manufacturer packaging and veterinary guidance for handling/storage.

Share Your Thoughts

Let others know your experience or advice regarding this medication.

This medication has not been reviewed by a veterinarian yet.